North America Glycomic Therapeutics Market Forecast to 2028 – COVID

North America Glycomic Therapeutics Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – Class (Isolated and Synthetic), Structures [Glycoproteins, Targeting Sialic Acid, Proteoglycans, Targeting Glycosaminoglycans, Glycosylphosphatidylinositol (GPI)-Anchored Proteins & Heparin Based Glycans, Targeting Glycosphingolipids, and Others], Indications (Thrombosis & Chemoprophylaxis, Anaemia, Anti-Adhesive & Anti-Inflammatory, Cataracts, Gaucher’s Disease, MPS-1 & IV, Cancer, Alzheimer’s Disease, Influenza Type A & B, and Others), Mode of Action [Inhibits Neuraminidase, Inhibits Heparanase and Selectins and Blocks Interactions Between Growth Factors and Heparan Sulfate, Erythropoietin & Enzyme Replacement Therapy (ERT),Tissue Plasminogen Activator, Inhibits Glucosylceramide Synthas Interleukin 1 and 2 and 3, Beta & Gamma Interferons, and Others]

Report Code : BMIRE00027508 | Region : North America | Industry : Pharmaceuticals | Published Date : 18/Nov/2022

The glycomic therapeutics market in North America is expected to grow from US$ 42,552.69 million in 2022 to US$ 1,00,790.58 million by 2028; it is estimated to grow at a CAGR of 15.5% from 2022 to 2028.

Application in Treatment of Broad Range of Disorders Drives Market Growth

Glycan-based products have wide applications in the therapeutic industry; the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, and anti-inflammation. The glycoprotein is a type of glycan that can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are a part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions.

For instance, in April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created SubB2M, a special protein that attaches itself exclusively to a sugar molecule, only found in cancer cells. The researchers have claimed that the protein might revolutionize cancer detection.

In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence centered at the University of Alberta for Glycomics Research, is providing the funds to enhance the quality of life of Canadians.

In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.

Market Overview

The North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US held the largest share of the North America glycomic therapeutics market in 2022. The increasing demand in the region, followed by rising research and development activities by various major firms, rising number of investments in glycomic therapeutics research, and growing awareness about glycomic therapeutics, is expected to drive the overall glycomic therapeutics market during the forecast period.

North America Glycomic Therapeutics Market Revenue and Forecast to 2028 (US$ Billion)

North America Glycomic Therapeutics Market Segmentation

The North America glycomic therapeutics market is segmented on the basis of class, structure, indications, mode of action, and country.

Based on class, the North America glycomic therapeutics market is bifurcated into isolated and synthetic. The synthetic segment registered a larger market share in 2022. Based on structure, the North America glycomic therapeutics market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI)-anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held the largest market share in 2022. Based on indications, the North America glycomic therapeutics market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, gaucher’s disease, MPS-1 & IV, cancer, Alzheimer's disease, influenza type A & B, and others. The influenza type a & b segment held the largest market share in 2022. Based on mode of action, the North America glycomic therapeutics market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held the largest market share in 2022. Based on country, the North America glycomic therapeutics market is segmented into the US, Canada, and Mexico. The US dominated the market in 2022. BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); HalozymeTherapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline plc.; and F. Hoffmann-La Roche Lt. are the leading companies operating in the glycomic therapeutics in North America.

At 15.5% CAGR, the North America Glycomic Therapeutics Market is speculated to be worth US$ 1,00,790.58 million by 2028, says The Insight Partners

According to The Insight Partners’ research, the North America glycomic therapeutics market was valued at US$ 42,552.69 million in 2022 and is expected to reach US$ 1,00,790.58 million by 2028, registering an annual growth rate of 15.5% from 2022 to 2028. Wide application in various disorders followed by the development of new treatment processes and increasing research and development in the field of glycomic therapeutics are the critical factors attributed to the market expansion.

Glycan-based products have wide applications in the therapeutic industry, the products are available in different structures & forms and developed as per the application. This drug is designed for various diseases, such as thrombosis, anaemia, cancer, influenza, cataract, anti-inflammation, and various others. The glycoprotein is a type of glycan can be used to deliver drugs, toxins, or radioactive substances directly to cancer cells. Monoclonal antibodies, including erythropoietin (EPO) and Herceptin (trastuzumab), are widely used and are part of several research projects. These products are aimed at expanding and improving their applicability and efficacy. EPO has been used to treat traumatic brain injury (TBI) in young patients and Alzheimer's disease in rodent models due to its known neuroprotective effects. The largest and fastest-growing application category is drug discovery and development, mostly due to the rise in R&D by pharmaceutical and biotechnology firms and the expansion of drug discovery research activities in university research institutions. For instance, In April 2020, researchers from the Institute for Glycomics and the University of Adelaide signed an exclusive licensing agreement with Sienna Cancer Diagnostics Ltd. to commercialize a cutting-edge cancer detection tool. The researchers have created a special protein, called SubB2M, which attaches exclusively to a sugar molecule, only found in cancer cells. The protein might revolutionize the cancer detection. In March 2021, 48Hour Discovery (48HD) and CQDM announced that the firms received an award of US$ 800,000 for peptide drug development utilizing its unique drug discovery platform. The CQDM Quantum Leap initiative, which encourages research into cutting-edge technologies, methods, and platforms that speed up or expedite drug discovery and development, provided funding for the two-year study. Merck, a CQDM member, is financing the study. The University of Alberta and 48HD will work together on the project. Additionally, GlycoNet, a Network of Centres of Excellence, centred at the University of Alberta for Glycomics Research, is providing the funds to enhance Canadians' quality of life. In March 2022, researchers from the Canadian Glycomics Network (GlycoNet) developed a novel combination medication for Sanfilippo syndrome, which is showing encouraging preclinical outcomes. Researchers at Kaleido Biosciences are developing therapeutics for immune-mediated and inflammatory diseases with synthetic glycans that are selectively metabolized in the gut microbiome to suppress the growth of bacteria associated with inflammation. One synthetic glycan candidate, KB295, is intended to treat ulcerative colitis, an inflammatory bowel disorder (IBD). The administration of microbiome-mediating glycans could radically improve treatment by 16% of IBD sufferers who do not respond to the current standard of care and other patients with hard-to-treat autoimmune and inflammatory conditions. These advancements show that glycomics has the potential to provide rapid and accurate therapeutic results for complex conditions. Therefore, the use of glycomics in drug development for diseases across the region drives the glycomics therapeutics market.

On the contrary, high cost of equipment hampers market North America glycomic therapeutics market.

Based on class, the market is segmented into isolated and synthetic. The synthetic segment held 68.98% market share in 2022, amassing US$ 29.35 billion. It is projected to garner US$ 68.62 billion by 2028 to expand at 14.8% CAGR during 2022–2028. Based on structure, the market is segmented into glycoproteins, targeting sialic acid, proteoglycans, targeting glycosaminoglycans, glycosylphosphatidylinositol (GPI) anchored proteins & heparin based glycans, targeting glycosphingolipids, and others. The glycoproteins segment held 43.12% market share in 2022, amassing US$ 18.35 billion. It is projected to garner US$ 43.66 billion by 2028 to expand at 15.5% CAGR during 2022–2028. Based on indications, the market is segmented into thrombosis & chemoprophylaxis, anaemia, anti-adhesive & anti-inflammatory, cataracts, Gaucher’s disease, mps-1 & iv, cancer, alzheimer’s disease, influenza type a & b, and others. The influenza type a & b segment held 35.93% market share in 2022, amassing US$ 15.29 billion. It is projected to garner US$ 37.34 billion by 2028 to expand at 16.0% CAGR during 2022–2028. Based on mode of action, the market is segmented into inhibits neuraminidase, inhibits heparanase and selectins and blocks interactions between growth factors and heparan sulfate, erythropoietin & enzyme replacement therapy (ERT), tissue plasminogen activator, inhibits glucosylceramide synthase, interleukin 1 and 2 and 3, beta & gamma interferons, and others. The erythropoietin & enzyme replacement therapy (ERT) segment held 39.58% market share in 2022, amassing US$ 16.84 billion. It is projected to garner US$ 39.53 billion by 2028 to expand at 15.3% CAGR during 2022–2028. Based on country, the North America glycomic therapeutics market has been categorized into US, Canada, and Mexico. Our regional analysis states that US captured 84.77% market share in 2022. It was assessed at US$ 36.07 billion in 2022 and is likely to hit US$ 84.77 billion by 2028, exhibiting a CAGR of 15.3% during the forecast period. Key players dominating the North America glycomic therapeutics market are BioMarin Pharmaceutical Inc.; Genzyme Corporation (Sanofi); Halozyme Therapeutics, Inc.; Bayer AG; Alzheon, Inc.; GlycoMar; GlaxoSmithKline Plc.; F. Hoffmann-La Roche Ltd.

In May,2022; Halozyme Therapeutics announced the completion of its acquisition of Antares Pharma, Inc. The acquisition aims to create specialty products. In May,2021; Alzheon, Inc. announced that it has entered into a collaboration and license agreement with the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences (IOCB) to develop the first clinical assay to measure neurotoxic beta-amyloid (amyloid, A?) oligomers in human cerebrospinal fluid (CSF). Under the collaboration agreement, IOCB applied Alzheon’s technology for detecting oligomers into a customized clinical assay in human CSF, to be developed by the IOCB and commercialized by Alzheon.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 North America Glycomic Therapeutics Market – By Class

1.3.2 North America Glycomic Therapeutics Market – By Structures

1.3.3 North America Glycomic Therapeutics Market – By Indications

1.3.4 North America Glycomic Therapeutics Market – By Mode of Action

1.3.5 North America Glycomic Therapeutics Market – By Country

2. North America Glycomic Therapeutics Market– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. North America Glycomic Therapeutics Market Landscape

4.1 Overview

4.2 North America PEST Analysis

4.3 Expert Opinion

5. North America Glycomic Therapeutics Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Wide Application in Various Disorders Followed by the Development of New Treatment Processes

5.1.2 Increasing Research and Development In the Field of Glycomic Therapeutics

5.2 Market Restraints

5.2.1 Shortage of Skilled Professionals and Lack of Research & Development laboratories in Developing Countries.

5.3 Market Opportunities

5.3.1 Wide Applications of Glycomics in Therapeutics

5.4 Future Trends

5.4.1 New Tools in Glycomics Research

5.5 Impact Analysis

6. Glycomic Therapeutics Market– North America Analysis

6.1 North America Glycomic Therapeutics Market Revenue Forecast and Analysis

6.1.1 North America: Glycomic Therapeutics Market, 2019-2028 (US$ Million)

7. North America Glycomic Therapeutics Market Revenue and Forecast to 2028– by Class

7.1 Overview

7.2 North America Glycomic Therapeutics Market, By Class 2022 & 2028 (%)

7.2.1 North America: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

7.3 Isolated

7.3.1 Overview

7.3.2 North America Isolated Revenue and Forecast to 2028 (US$ Million)

7.4 Synthetic

7.4.1 Overview

7.4.2 North America Synthetic - Revenue and Forecast to 2028 (US$ Million)

8. North America Glycomics Therapeutics Market Analysis and Forecasts To 2028 – By Indication

8.1 Overview

8.2 North America Glycomics Market, By Indication 2022 & 2028 (%)

8.2.1 North America: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

8.3 Thrombosis and Chemoprophylaxis

8.3.1 Overview

8.3.2 North America Thrombosis and chemoprophylaxis Revenue and Forecast to 2028 (US$ Million)

8.4 Anaemia

8.4.1 Overview

8.4.2 North America Anaemia Revenue and Forecast to 2028 (US$ Million)

8.5 Anti-adhesive and Anti-inflammatory

8.5.1 Overview

8.5.2 North America Anti-adhesive and Anti-inflammatory Revenue and Forecast to 2028 (US$ Million)

8.6 Cataract

8.6.1 Overview

8.6.2 North America Cataract Revenue and Forecast to 2028 (US$ Million)

8.7 Gaucher’s diseases

8.7.1 Overview

8.7.2 North America Gaucher’s diseases Revenue and Forecast to 2028 (US$ Million)

8.8 MPS-1 & IV

8.8.1 Overview

8.8.2 North America MPS-1 & IV Revenue and Forecast to 2028 (US$ Million)

8.9 Cancer

8.9.1 Overview

8.9.2 North America Cancer Revenue and Forecast to 2028 (US$ Million)

8.10 Alzheimer's

8.10.1 Overview

8.10.2 North America Alzheimer's Revenue and Forecast to 2028 (US$ Million)

8.11 Influenza Type A and B

8.11.1 Overview

8.11.2 North America Influenza Type A and B Revenue and Forecast to 2028 (US$ Million)

8.12 Others

8.12.1 Overview

8.12.2 North America Others Revenue and Forecast to 2028 (US$ Million)

9. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Structures

9.1 Overview

9.2 North America Glycomic Therapeutics Market, By Structures 2022 & 2028 (%)

9.2.1 North America: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

9.2.1.1 North America: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

9.2.1.2 North America: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

9.2.1.3 North America: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

9.2.1.4 North America: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

9.3 Glycoproteins

9.3.1 Overview

9.3.2 North America Glycoproteins - Market Revenue and Forecast to 2028 (US$ Million)

9.4 Targeting Sialic Acid

9.4.1 Overview

9.4.2 North America Targeting Sialic Acid - Market Revenue and Forecast to 2028 (US$ Million)

9.4.3 Zanamivir

9.4.3.1 Overview

9.4.3.2 North America Zanamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.4.4 Oseltamivir

9.4.4.1 Overview

9.4.4.2 North America Oseltamivir - Market Revenue and Forecast to 2028 (US$ Million)

9.5 Proteoglycans

9.5.1 Overview

9.5.2 North America Proteoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.6 Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans

9.6.1 Overview

9.6.2 North America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7 Targeting Glycosaminoglycans

9.7.1 Overview

9.7.2 North America Targeting Glycosaminoglycans - Market Revenue and Forecast to 2028 (US$ Million)

9.7.3 Heparin

9.7.3.1 Overview

9.7.3.2 North America Heparin - Market Revenue and Forecast to 2028 (US$ Million)

9.7.4 Hyaluronan (HA)

9.7.4.1 Overview

9.7.4.2 North America Hyaluronan (HA)- Market Revenue and Forecast to 2028 (US$ Million)

9.7.5 Laronidase

9.7.5.1 Overview

9.7.5.2 North America Laronidase - Market Revenue and Forecast to 2028 (US$ Million)

9.7.6 Galsulfase (Naglazyme)

9.7.6.1 Overview

9.7.6.2 North America Galsulfase (Naglazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.7 Hyaluronidase (Cumulase)

9.7.7.1 Overview

9.7.7.2 North America Hyaluronidase (Cumulase) - Market Revenue and Forecast to 2028 (US$ Million)

9.7.8 Others

9.7.8.1 Overview

9.7.8.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.8 Targeting Glycosphingolipids

9.8.1 Overview

9.8.2 North America Targeting Glycosphingolipids - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3 Imiglucerase (Cerezyme)

9.8.3.1 Overview

9.8.3.2 North America Imiglucerase (Cerezyme)- Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.3 Agalsidase (Fabrazyme)

9.8.3.3.1 Overview

9.8.3.3.2 North America Agalsidase (Fabrazyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.3.4 N-butyl-deoxynojirimycin (DNJ)

9.8.3.4.1 Overview

9.8.3.4.2 North America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecast to 2028 (US$ Million)

9.8.4 Others

9.8.4.1 Overview

9.8.4.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9 Others

9.9.1 Overview

9.9.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3 Acarbose

9.9.3.1 Overview

9.9.3.2 North America Acarbose - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.3 Alglucosidase Alfa (Myozyme)

9.9.3.3.1 Overview

9.9.3.3.2 North America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecast to 2028 (US$ Million)

9.9.3.4 Allosamidin

9.9.3.4.1 Overview

9.9.3.4.2 North America Allosamidin - Market Revenue and Forecast to 2028 (US$ Million)

9.9.4 Others

9.9.4.1 Overview

9.9.4.2 North America Others - Market Revenue and Forecast to 2028 (US$ Million)

10. North America Glycomic Therapeutics Market Revenue and Forecast to 2028 – by Mode of Action

10.1 Overview

10.2 North America Glycomic Therapeutics Market, By Mode of Action 2022 & 2028 (%)

10.2.1 North America: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

10.3 Inhibits Neuraminidase

10.3.1 Overview

10.3.2 North America Inhibits Neuraminidase - Market Revenue and Forecast to 2028 (US$ Million)

10.4 Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate

10.4.1 Overview

10.4.2 North America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecast to 2028 (US$ Million)

10.5 Erythropoietin And Enzyme Replacement Therapy (ERT)

10.5.1 Overview

10.5.2 North America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecast to 2028 (US$ Million)

10.6 Tissue Plasminogen Activator

10.6.1 Overview

10.6.2 North America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

10.7 Inhibits Glucosylceramide Synthase

10.7.1 Overview

10.7.2 North America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

10.8 Interleukin 1 And 2 And 3

10.8.1 Overview

10.8.2 North America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

10.9 Beta And Gamma Interferons

10.9.1 Overview

10.9.2 North America Beta And Gamma Interferons- Market Revenue And Forecasts To 2028 (US$ Million)

10.10 Others

10.10.1 Overview

10.10.2 North America Others- Market Revenue And Forecasts To 2028 (US$ Million)

11. North America Glycomic Therapeutics Market Revenue and Forecasts to 2028 – Country Analysis

11.1 North America: Glycomic Therapeutics Market

11.1.1 Overview

11.1.2 North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

11.1.3 US: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.1 Overview

11.1.3.1.2 US: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.1.3 US: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.3.1.4 US: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.3.1.4.1 US: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.3.1.4.2 US: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.3.1.4.3 US: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.3.1.4.4 US: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.3.1.5 US: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.3.1.6 US: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.3.2 Canada: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.1 Overview

11.1.3.2.2 Canada: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.2.3 Canada: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.3.2.4 Canada: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.3.2.4.1 Canada: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.3.2.4.2 Canada: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.3.2.4.3 Canada: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.3.2.4.4 Canada: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.3.2.5 Canada: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.3.2.6 Canada: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

11.1.3.3 Mexico: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.1 Overview

11.1.3.3.2 Mexico: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

11.1.3.3.3 Mexico: Glycomic Therapeutics Market, by Class, 2019-2028 (US$ Million)

11.1.3.3.4 Mexico: Glycomic Therapeutics Market, by Structure, 2019-2028 (US$ Million)

11.1.3.3.4.1 Mexico: Glycomic Therapeutics Market, by Targeting Sialic Acid, 2019-2028 (US$ Million)

11.1.3.3.4.2 Mexico: Glycomic Therapeutics Market, by Targeting Glycosaminoglycan, 2019-2028 (US$ Million)

11.1.3.3.4.3 Mexico: Glycomic Therapeutics Market, by Targeting Glycosphingolipids, 2019-2028 (US$ Million)

11.1.3.3.4.4 Mexico: Glycomic Therapeutics Market, by Others, 2019-2028 (US$ Million)

11.1.3.3.5 Mexico: Glycomic Therapeutics Market, by Indication, 2019-2028 (US$ Million)

11.1.3.3.6 Mexico: Glycomic Therapeutics Market, by Mode of Action, 2019-2028 (US$ Million)

12. Glycomic Therapeutics Market –Industry Landscape

12.1 Overview

12.2 Growth Strategies in the Glycomic Therapeutics Market (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 BioMarin Pharmaceutical Inc.

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Genzyme Corporation (Sanofi)

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Halozyme Therapeutics, Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Bayer AG

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Alzheon, Inc.

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 GlaxoSmithKline plc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 F. Hoffmann-La Roche Ltd

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms in Glycomic Therapeutics Market

LIST OF TABLES.

Table 1. North America Glycomic Therapeutics Market, Revenue and Forecast to 2028 (US$ Million)

Table 2. North America Glycomic Therapeutics Market, by C lass – Revenue and Forecast to 2028 (US$ Million)

Table 3. North America Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 4. North America Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 5. North America Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 6. North America Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 7. North America Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 8. North America Glycomic Therapeutics Market, by Others– Revenue and Forecast to 2028 (USD Million)

Table 9. North America Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 10. US Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (USD Million)

Table 11. US Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 12. US Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 13. US Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 14. US Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 15. US Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (USD Million)

Table 16. US Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 17. US Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 18. Canada Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (USD Million)

Table 19. Canada Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (USD Million)

Table 20. Canada Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (USD Million)

Table 21. Canada Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (USD Million)

Table 22. Canada Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (USD Million)

Table 23. Canada Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (USD Million)

Table 24. Canada Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (USD Million)

Table 25. Canada Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (USD Million)

Table 26. Mexico Glycomic Therapeutics Market, by Class – Revenue and Forecast to 2028 (US$ Million)

Table 27. Mexico Glycomic Therapeutics Market, by Structure – Revenue and Forecast to 2028 (US$ Million)

Table 28. Mexico Glycomic Therapeutics Market, by Targeting Sialic Acid – Revenue and Forecast to 2028 (US$ Million)

Table 29. Mexico Glycomic Therapeutics Market, by Targeting Glycosaminoglycan – Revenue and Forecast to 2028 (US$ Million)

Table 30. Mexico Glycomic Therapeutics Market, by Targeting Glycosphingolipids – Revenue and Forecast to 2028 (US$ Million)

Table 31. Mexico Glycomic Therapeutics Market, by Others – Revenue and Forecast to 2028 (US$ Million)

Table 32. Mexico Glycomic Therapeutics Market, by Indication – Revenue and Forecast to 2028 (US$ Million)

Table 33. Mexico Glycomic Therapeutics Market, by Mode of Action – Revenue and Forecast to 2028 (US$ Million)

Table 34. Organic Developments in the Glycomic Therapeutics Market

Table 35. Inorganic Developments in the Glycomic Therapeutics Market

Table 36. Glossary of Terms in Glycomic Therapeutics Market

LIST OF FIGURES.

Figure 1. North America Glycomic Therapeutics Market Segmentation

Figure 2. North America Glycomic Therapeutics Market, By Country

Figure 3. North America Glycomic Therapeutics Market Overview

Figure 4. Synthetic Segment Held Largest Share of Class Segment in North America Glycomic Therapeutics Market

Figure 5. Canada is Expected to Show Remarkable Growth During the Forecast Period

Figure 6. North America: PEST Analysis

Figure 7. North America Glycomic Therapeutics Market Impact Analysis of Driver and Restraints

Figure 8. North America Glycomics market – Revenue Forecast And Analysis – 2020- 2028

Figure 9. North America Glycomic Therapeutics Market, by Class 2022 & 2028 (%)

Figure 10. North America Isolated Revenue and Forecasts to 2028 (US$ Million)

Figure 11. North America Synthetic - Revenue and Forecasts to 2028 (US$ Million)

Figure 12. North America Glycomics Market, by Indication 2022 & 2028 (%)

Figure 13. North America Thrombosis and chemoprophylaxis Revenue and Forecasts to 2028 (US$ Million)

Figure 14. North America Anaemia Revenue and Forecasts to 2028 (US$ Million)

Figure 15. North America Anti-adhesive and Anti-inflammatory Revenue and Forecasts to 2028 (US$ Million)

Figure 16. North America Cataract Revenue and Forecasts to 2028 (US$ Million)

Figure 17. North America Gaucher’s diseases Revenue and Forecasts to 2028 (US$ Million)

Figure 18. North America MPS-1 & IV Revenue and Forecasts to 2028 (US$ Million)

Figure 19. North America Cancer Revenue and Forecasts to 2028 (US$ Million)

Figure 20. North America Alzheimer's Revenue and Forecasts to 2028 (US$ Million)

Figure 21. North America Influenza Type A and B Revenue and Forecasts to 2028 (US$ Million)

Figure 22. North America Others Revenue and Forecasts to 2028 (US$ Million)

Figure 23. North America Glycomic Therapeutics Market, by Structures 2022 & 2028 (%)

Figure 24. North America Glycoproteins - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 25. North America Targeting Sialic Acid - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 26. North America Zanamivir - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 27. North America Oseltamivir - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 28. North America Proteoglycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 29. North America Glycosylphosphatidylinositol (GPI)-Anchored Proteins and Heparin Based Glycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 30. North America Targeting Glycosaminoglycans - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 31. North America Heparin - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 32. North America Hyaluronan (HA) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 33. North America Laronidase - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 34. North America Galsulfase (Naglazyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 35. North America Hyaluronidase (Cumulase) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 36. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 37. North America Targeting Glycosphingolipids - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 38. North America Imiglucerase (Cerezyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 39. North America Agalsidase (Fabrazyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 40. North America N-butyl-deoxynojirimycin (DNJ) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 41. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 42. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 43. North America Acarbose - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 44. North America Alglucosidase Alfa (Myozyme) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 45. North America Allosamidin - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 46. North America Others - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 47. North America Glycomic Therapeutics Market, by Mode of Action 2022 & 2028 (%)

Figure 48. North America Inhibits Neuraminidase - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 49. North America Inhibits Heparanase And Selectins And Blocks Interactions Between Growth Factors And Heparan Sulfate - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 50. North America Erythropoietin And Enzyme Replacement Therapy (ERT) - Market Revenue and Forecasts to 2028 (US$ Million)

Figure 51. North America Tissue Plasminogen Activator - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 52. North America Inhibits Glucosylceramide Synthase - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 53. North America Interleukin 1 And 2 And 3- Market Revenue And Forecasts To 2028 (US$ Million)

Figure 54. North America Beta And Gamma Interferons - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 55. North America Others - Market Revenue And Forecasts To 2028 (US$ Million)

Figure 56. North America: Glycomic Therapeutics Market, by Key Country – Revenue (2022) (US$ Million)

Figure 57. North America: Glycomic Therapeutics Market, by Country, 2021 & 2028 (%)

Figure 58. US: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 59. Canada: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 60. Mexico: Glycomic Therapeutics Market – Revenue and Forecast to 2028 (US$ Million)

Figure 61. Growth Strategies in the Glycomic Therapeutics Market (%)

The List of Companies - North America Glycomic Therapeutics Market

● BioMarin Pharmaceutical Inc.                    

● Genzyme Corporation (Sanofi)                 

● Halozyme Therapeutics, Inc.                      

● Bayer AG                                                            

● Alzheon, Inc.                                                     

● GlycoMar                                                           

● GlaxoSmithKline plc.                   

● F. Hoffmann-La Roche Ltd

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America Glycomic Therapeutics Market.

● Highlights key business priorities in order to assist companies to realign their business strategies.

● The key findings and recommendations highlight crucial progressive industry trends in North America Glycomic Therapeutics Market, thereby allowing players across the value chain to develop effective long-term strategies.

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.

● Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.

● Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TOP